|
in:
|
|
| Forums > Talk About It! > Medicinal Cannabis Forum > Hepatitis C | ||
| Hepatitis C | Thread Tools | Search this Thread |
|
|
#11 |
|
Member
Join Date: Jan 2004
Location: Gulf of Mexico
Posts: 39
![]() |
You will never know how much I truly appreciate your input. I did seek a few more opinions and at my doctor's and wife's urging, I am now on my second day with it. Nothing noticeably diiferent yet. Sure wish that I had access to a decent sativa to use instead. Oh well, once again, wishful thinking gets me nowhere and everybody knows that this is nowhere.... .
__________________
Life is good... Last edited by Buffalo Bill; 03-08-2004 at 08:38 PM.. |
|
|
|
|
|
#12 |
|
Member
Join Date: Feb 2004
Location: follow the smoke
Posts: 294
![]() ![]() ![]() ![]() ![]() ![]() |
hello bb, you can also try a natural aproach thatt include some special food regime and some plants also can help like
silybum marianum wich is rich in slimarym and very efective for liver regeneration ganoderma lucidum its mursrom thatt show very good results. i can send you more information if you want Last edited by agro; 03-16-2004 at 07:55 PM.. |
|
|
|
|
|
#13 |
|
Member
Join Date: Jan 2004
Location: Gulf of Mexico
Posts: 39
![]() |
Agro, I am familiar with silybin and I take in the form of Maximum Milk Thistle, perhaps you can give me with a bit more information or better yet point me the way to a website address for the ganoderma lucidum. Thanks in advance! Take care and be cooool...
__________________
Life is good... |
|
|
|
|
|
#14 |
|
Member
Join Date: Feb 2004
Location: follow the smoke
Posts: 294
![]() ![]() ![]() ![]() ![]() ![]() |
some information about ganoderma
https://www.begellhouse.com/journals/...418679e96.html A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis  Yihuai Gao Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore 117543, Singapore; and Division of Pharmacology and Clinical Pharmacology, Faculty of Medicine and Health Science, The University of Auckland, Auckland, New Zealand Guoliang Chen Shanghai Academy of Agricultural Sciences, Shanghai, China Xihu Dai Fuzhou General Hospital of Nanjing Military Region of the Peoples' Liberation Army, Fuzhou, Fujian, China Jingxian Ye Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China He Gao New Zealand Institute of Natural Medicines, Auckland, New Zealand ABSTRACT The polysaccharide fractions and triterpenes isolated from Ganoderma lucidum have shown protection effects on the liver in animal studies. This double-blind, randomised, and multicentered study aimed to evaluate the safety and effect of a G. lucidum extraction, Ganopoly, in chronic hepatitis B. Ninety patients with chronic hepatitis B, hepatitis  viral (HBV) DNA positivity, and aminotransferase elevation were included in this multicenter prospective randomized Phase I/II study. Patients were randomized to be given Ganopoly (n = 60) or placebo (n = 30) for 12 weeks, then followed up for 13 weeks. Effect of therapy on levels of HBV DNA and aminotransferase activities in serum and hepatitis  å antigen (HBeAg) status were investigated. There were 78 assessable patients who entered the trial for efficacy and safety; 13 of 52 (25%) patients receiving Ganopoly responded by reducing HBeAg and HBV DNA, compared to 1 of 26 (4%) in the control group (P < 0.05). Among those with serum aspartate aminotransferase (AST) values < 100 U/L (n = 29), 41% (12/29) responded, and among those with AST values > 100 U/L (n = 23), 65% (15/23) responded. Within the 6-month study period, 33% (17/ 52) of treated patients had normal aminotransferase (ALT) values, and 13% (7/52) had cleared hepatitis B surface antigen (HBsAg) from serum, whereas none of the controls had normal ALT values or had lost HBsAg. Eight of 60 patients in Ganopoly group and 4 of 30 in the controls were unable to be followed up due to loss or withdrawal. Our study indicates that Ganopoly is well tolerated and appears to be active against HBV in patients with chronic hepatitis B. Last edited by agro; 03-17-2004 at 10:40 AM.. |
|
|
|
|
|
|
|